[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338264-105":59,"doc-detail-338264-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","deciphering-resistance-mechanisms-in-cancer-final-report-of-match-r-study-with-a-focus-on-molecular-drivers-and-pdx-development","Deciphering resistance mechanisms in cancer - final report of MATCH-R study - with a focus on molecular drivers and PDX development","","Understanding tumor resistance mechanisms is crucial for advancing cancer therapies. The prospective MATCH-R trial (NCT02517892), led by Gustave Roussy, analyzed resistance to cancer treatments using molecular profiling of fresh tumor biopsies. This report summarizes genomic analyses from 2015–2022, combining targeted NGS, whole-exome sequencing, and RNA sequencing with patient-derived xenograft (PDX) development to support targeted, personalized treatment decisions.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/deciphering-resistance-mechanisms-in-cancer-final-report-of-match-r-study-with-a-focus-on-molecular-drivers-and-pdx-development/338264/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/deciphering-resistance-mechanisms-in-cancer-final-report-of-match-r-study-with-a-focus-on-molecular-drivers-and-pdx-development/338264.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the purpose of the MATCH-R trial?","Question",{"text":113,"@type":114},"The MATCH-R trial aimed to characterize mechanisms of resistance to cancer treatments by performing molecular analysis on fresh tumor biopsies from resistant metastatic patients.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were molecular analyses performed in the study?",{"text":118,"@type":114},"Tumor content in frozen biopsies was assessed, followed by targeted NGS (or whole-exome sequencing) and RNA sequencing before and/or after anticancer therapy, depending on tumor content thresholds.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the study find about actionable molecular drivers and resistance types?",{"text":122,"@type":114},"Actionable molecular driver alterations were identified in 30.9% of patients; among progression on targeted therapy, resistance included cases without identifiable mechanisms, on-target resistance, and bypass resistance mechanisms.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338264,1790199852,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Vasseur et al. Molecular Cancer (2024) 23:221 [https://doi.org/10.1186/s12943-024-02134-4](https://doi.org/10.1186/s12943-024-02134-4)  \nMolecular Cancer  \n RESEARCH Open Access  \nDeciphering resistance mechanisms   in cancer: final report of MATCH-R study  \nwith a focus on molecular drivers and PDX development  \nDamien Vasseur1,2†, Ludovic Bigot3†, Kristi Beshiri4†, Juan Flórez-Arango3, Francesco Facchinetti3, Antoine Hollebecque4,5, Lambros Tselikas6, Mihaela Aldea5, Felix Blanc-Durand5, Anas Gazzah4,  \nDavid Planchard5, Ludovic Lacroix1,2, Noémie Pata-Merci2, Catline Nobre3, Alice Da Silva3, Claudio Nicotra4, Maud Ngo-Camus4, Floriane Braye3, Sergey I. Nikolaev3, Stefan Michiels7,8, Gérôme Jules-Clement9, Ken André Olaussen3, Fabrice André3,5, Jean-Yves Scoazec 1,2, Fabrice Barlesi5, Santiago Ponce3,5,  \nJean-Charles Soria3,5, Benjamin Besse3,5, Yohann Loriot3,4,5* and Luc Friboulet3*  \nAbstract  \nBackground Understanding the resistance mechanisms of tumor is crucial for advancing cancer therapies. The prospective MATCH-R trial (NCT02517892), led by Gustave Roussy, aimed to characterize resistance mechanisms to cancer treatments through molecular analysis of fresh tumor biopsies. This report presents the genomic data analysis of the MATCH-R study conducted from 2015 to 2022 and focuses on targeted therapies.  \nMethods The study included resistant metastatic patients (pts) who accepted an image-guided tumor biopsy. After evaluation of tumor content (TC) in frozen tissue biopsies, targeted NGS (10 \u003C TC \u003C 30%) or Whole Exome Sequencing and RNA sequencing (TC >30%) were performed before and/or after the anticancer therapy.  \nPatient-derived xenografts (PDX) were established by implanting tumor fragments into NOD scid gamma mice and amplified up to five passages.  \nResults A total of 1,120 biopsies were collected from 857 pts with the most frequent tumor types being lung (38 . 8%), digestive (16 . 3%) and prostate (14 . 1%) cancer. Molecular targetable driver were identified in 30. 9%(n= 265/857) of the patients, with EGFR (41 . 5%), FGFR2/3 (15 . 5%), ALK (11 . 7%), BRAF (6 . 8%), and KRAS (5 . 7%) being the most common altered genes. Furthermore, 66 . 0%(n= 175/265) had a biopsy at progression on targeted therapy. Among resistant cases, 41 . 1%(n= 72/175) had no identified molecular mechanism, 32 . 0%(n= 56/175) showed on-target resistance, and 25 . 1%(n= 44/175) exhibited a by-pass resistance mechanism. Molecular profiling of the 44 patients with by-pass resistance identified 51 variants, with KRAS (13 . 7%), PIK3CA (11 . 8%), PTEN (11 . 8%), NF2 (7 . 8%), AKT1 (5 . 9%), and NF1  \n†Damien Vasseur, Ludovic Bigot and Kristi Beshiri contributed equally to this work.  \n*Correspondence:  \nYohann Loriot [yohann.loriot@gustaveroussy.fr](yohann.loriot@gustaveroussy.fr)[ ](yohann.loriot@gustaveroussy.fr)Luc Friboulet  \nluc.friboulet@gustaveroussy.fr  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/","cbCaian5gZ3VjTTb","https://ap.wps.com/l/cbCaian5gZ3VjTTb","pdf",4666710,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the purpose of the MATCH-R trial?\",\"answer\":\"The MATCH-R trial aimed to characterize mechanisms of resistance to cancer treatments by performing molecular analysis on fresh tumor biopsies from resistant metastatic patients.\"},{\"question\":\"How were molecular analyses performed in the study?\",\"answer\":\"Tumor content in frozen biopsies was assessed, followed by targeted NGS (or whole-exome sequencing) and RNA sequencing before and/or after anticancer therapy, depending on tumor content thresholds.\"},{\"question\":\"What did the study find about actionable molecular drivers and resistance types?\",\"answer\":\"Actionable molecular driver alterations were identified in 30.9% of patients; among progression on targeted therapy, resistance included cases without identifiable mechanisms, on-target resistance, and bypass resistance mechanisms.\"}]","Deciphering resistance mechanisms in cancer - final report of MATCH-R study - with a focus on molecular drivers and PDX development | PDF",1790022826,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3ce366d97197144bcb3051608fae5db.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36368a785e1ea3731a19af8afdf55c39.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/599d9e9c92bf8b1d2929d6f11eb1616b.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b744c63fd6da525de3cc4293140ddf6e.webp",980,1301]